IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by HUB Investment Partners LLC

HUB Investment Partners LLC reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 6.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,035 shares of the company's stock after selling 2,687 shares during the period. HUB Investment Partners LLC's holdings in IDEXX Laboratories were worth $16,552,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. FSA Wealth Management LLC purchased a new position in IDEXX Laboratories in the 3rd quarter worth approximately $25,000. Rialto Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at approximately $30,000. Retirement Wealth Solutions LLC purchased a new position in IDEXX Laboratories during the fourth quarter worth approximately $31,000. Kestra Investment Management LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth $38,000. Finally, Crews Bank & Trust purchased a new stake in IDEXX Laboratories in the 4th quarter valued at $41,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Up 0.6 %

Shares of NASDAQ IDXX traded up $2.61 during mid-day trading on Monday, hitting $423.60. The company had a trading volume of 616,827 shares, compared to its average volume of 552,334. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $548.88. The company has a market capitalization of $34.34 billion, a PE ratio of 39.70, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The business's 50-day simple moving average is $437.38 and its 200 day simple moving average is $444.44.

Remove Ads

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company's stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the business's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

IDXX has been the topic of several analyst reports. Leerink Partners assumed coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an "outperform" rating and a $500.00 price target on the stock. StockNews.com downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday, March 15th. Morgan Stanley decreased their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Piper Sandler lifted their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Finally, Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.